STOCK TITAN

SciSparc Ltd - SPRC STOCK NEWS

Welcome to our dedicated news page for SciSparc (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on SciSparc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SciSparc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SciSparc's position in the market.

Rhea-AI Summary
SciSparc announces collaboration with Clearmind Medicine Inc. for novel therapy to treat depression. Clearmind submits patent application for MEAI compound combined with SciSparc's CannAmide™. Global depression and anxiety disorders treatment market expected to reach USD 41.83 billion by 2034.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.45%
Tags
none
-
Rhea-AI Summary
SciSparc announces MitoCareX Bio's successful identification of potential anti-cancer small molecules through advanced drug discovery platform and in-vitro screening systems, leading to the development of a predictive AI model for more efficient drug discovery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
none
-
Rhea-AI Summary
SciSparc (Nasdaq: SPRC) secures a patent for its core technology combining cannabinoids and n-acylethanolamines from the Canadian Intellectual Property Office. The patent aims to enhance the safety of cannabinoids with low dosages while maintaining therapeutic benefits, supporting the company's innovative technologies for central nervous system disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.1%
Tags
none
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) has dosed the first patient in a clinical trial for Autism Spectrum Disorder in pediatric patients. The trial is for SCI-210 at Soroka Medical Center, marking a crucial advancement in treating rare diseases of the central nervous system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
clinical trial
-
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) announces MitoCareX Bio's progress in utilizing a predictive AI model to identify potential anti-cancer treatments. MitoCareX screened millions of small molecules, confirming anti-cancer activity through in-vitro testing. The company aims to enhance drug discovery efficiency by developing a predictive AI model.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.78%
Tags
none
-
Rhea-AI Summary
SciSparc Ltd. announces enrollment of the first patient in a clinical trial for SCI-210, a treatment for children with autism spectrum disorder. The company aims to address the unmet need for efficient and safe treatments in this area.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.11%
Tags
clinical trial
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) announces the completion of the granting and validation process for its core-technology patent covering combinations of cannabinoids and n-acylethanolamines in certain European countries. This patent enhances the safety of cannabinoids, maintaining therapeutic benefits with low dosages of active components. The Patent was granted and validated in multiple European countries, supporting SciSparc's innovative technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
-
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) receives patent approval for its proprietary combination of opioids and n-acylethanolamines for pain treatment from the Canadian Intellectual Property Office. The global opioid market is valued at $22.8 billion in 2022 and is expected to grow at a CAGR of 1.4% from 2023 to 2030. SciSparc aims to improve the therapeutic effect of opiates in lower doses to reduce their addictive potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
-
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) has successfully completed manufacturing and delivering its SCI-210 treatment for a clinical trial on pediatric patients with Autism Spectrum Disorder (ASD). The trial will evaluate the safety, tolerability, and efficacy of SCI-210 compared to CBD monotherapy, with primary endpoints including the Aberrant Behavior Checklist-Community (ABC-C) and Clinical Global Impressions-Improvement (CGI-I) scale.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
clinical trial
Rhea-AI Summary
SciSparc Ltd. announces collaboration with Clearmind Medicine Inc. for patent applications on novel psychedelic-derived therapeutics, focusing on mental health disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
partnership
SciSparc Ltd

Nasdaq:SPRC

SPRC Rankings

SPRC Stock Data

1.94M
258.69k
0.07%
8.85%
12.68%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
Tel Aviv